Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion
A randomized clinical trial
Keywords:
Bevacizumab, Intravitreal Injections, Retinal Vein Occlusion, TriamcinoloneAbstract
Background: Central retinal vein occlusion (CRVO), is the second-most common disorder after diabetic retinopathy that threatens the vision related to retinal vessels. One of the main reasons of vision loss is CRVO in acute and chronic forms.
Objective: The aim of this study was to investigate the response to intravitreal injection of triamcinolone, bevacizumab, and a combined form in patients with CRVO.
Methods: This study was a double-blinded randomized clinical trial conducted on patients with CRVO who were referred to the ophthalmology clinic of Urmia Imam Khomeini Hospital from May 2015 to May 2016. In total, ninety patients were divided into three groups using random numbers table. The first group received intravitreal triamcinolone acetonide (IVT) for treatment of macular edema due to CRVO, the second group received intravitreal bevacizumab (IVB) and the third group received a combination of IVT and IVB. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded and analyzed using optical coherence tomography system.
Results: In this study a total of 90 eyes were studied, 41 case (45.55%) were male and 49 cases (54.44%) were female. The mean age of patients was 68.41±8.32 years. The mean score of final visual acuity was 0.293±0.11 in the IVT group, 0.25±0.10 in the IVB group and 0.48±0.15 in the IVB+IVT group. The differences between groups considering final visual acuity was significant (p<0.001). The mean thickness of final macular was 383.33±97.70 micrometer in IVT group, 386.33±136.79 micrometers in IVB group and 307.33±110.79 micrometers in IVT+IVB group which were significant (p=0.014).
Conclusion: Using a combination of bevacizumab and triamcinolone in the treatment of central retinal vein occlusion compared with using each of them separately, had a better result and can be used as a solution in this disease.
Trial registration: The trial was registered at the Thai Registry of Clinical Trials (http://www.clinicaltrials.in.th) with the TCTR ID: TCTR20170612005.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
References
Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch
retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010; 117(6): 1094-1101.e5.
doi: 10.1016/j.ophtha.2010.01.058. PMID: 20430447.
Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye
Study. Trans Am Ophthalmol Soc. 2000; 98: 133-41. PMID: 11190017, PMCID: PMC1298220.
McAllister IL. Central retinal vein occlusion: a review. Clin Exp Ophthalmol. 2012; 40(1): 48-58. doi:
1111/j.1442-9071.2011.02713.x. PMID: 22003973.
Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, et al. Management of
retinal vein occlusion--consensus document. Ophthalmologica. 2011; 226(1): 4-28. PMID: 21577038.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor
in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;
(22): 1480-7. doi: 10.1056/NEJM199412013312203. PMID: 7526212.
Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in
human central retinal vein occlusion. Ophthalmology. 1998; 105(3): 412-6. doi: 10.1016/S0161- 6420(98)93020-2. PMID: 9499769.
Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular
degeneration. Can J Ophthalmol. 2005; 40(3): 352-68. doi: 10.1016/S0008-4182(05)80078-X. PMID:
Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, et al. Intravitreal levels of
vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal
vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006; 244(3): 309-15. doi: 10.1007/s00417-004-1087- 4. PMID: 16133018.
Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid
reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992; 110(8):
-9. PMID: 1497531.
Bezatis A, Spital G, Hohn F, Maier M, Clemens CR, Wachtlin J, et al. Functional and anatomical results
after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up -- the SOLO
study. Acta Ophthalmol. 2013; 91(5): e340-7. doi: 10.1111/aos.12020. PMID: 23638803.
Joshi L, Tomkins-Netzer O, Menezo V, Sallam A, Kirkpatrick N, Lightman S, et al. Dexamethasone
implants and neovascular glaucoma in central retinal vein occlusion. Acta Ophthalmol. 2013; 91(3): e239- 40. doi: 10.1111/aos.12009. PMID: 23241218.
Matonti F, Meyer F, Guigou S, Barthelemy T, Dumas S, Gobert F, et al. Ozurdex in the management of the
macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol. 2013; 91(7): e584-6.
doi: 10.1111/aos.12190. PMID: 23764276.
Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the
expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J
Pharmacol. 1998; 341(2-3): 309-15. PMID: 9543253.
Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kadkhodaei S. Intravitreal triamcinolone for acute
central retinal vein occlusion; a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2006;
(12): 1601-6. doi: 10.1007/s00417-006-0348-9. PMID: 16738858.
Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing
the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with
macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal
Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009; 127(9): 1101-14. doi:
1001/archophthalmol.2009.234. PMID: 19752419, PMCID: PMC2872173.
Algvere PV, Epstein D, von Wendt G, Seregard S, Kvanta A. Intravitreal bevacizumab in central retinal
vein occlusion: 18-month results of a prospective clinical trial. Eur J Ophthalmol. 2011; 21(6): 789-95. doi:
5301/EJO.2011.6522. PMID: 21484753.
Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, et al. Sustained benefits from
ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase
III study. Ophthalmology. 2011; 118(10): 2041-9. doi: 10.1016/j.ophtha.2011.02.038. PMID: 21715011.
Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Bevacizumab for macular edema in central
retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology. 2012;
(6): 1184-9. doi: 10.1016/j.ophtha.2012.01.022. PMID: 22424833.
Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to
retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012; 119(4): 802-9.
doi: 10.1016/j.ophtha.2011.12.005. PMID: 22301066.
Varma R, Bressler NM, Suner I, Lee P, Dolan CM, Ward J, et al. Improved vision-related function after
ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials.
Ophthalmology. 2012; 119(10): 2108-18. doi: 10.1016/j.ophtha.2012.05.017. PMID: 22817833.
Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab for treatment of macular edema secondary to
central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther. 2011;
(6): 615-21. doi: 10.1089/jop.2011.0050. PMID: 21823986.
Ramezani A, Esfandiari H, Entezari M, Moradian S, Soheilian M, Dehsarvi B, et al. Three intravitreal
bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion.
Acta Ophthalmol. 2014; 92(7): e530-9. doi: 10.1111/aos.12317. PMID: 24373344.
Abdelghany AI, Mahmoud M, Alazab EA, Ghazy MI, Abdallah MA. Prospective study of single
intravitreal triamcinolone acetonide versus bevacizumab for treatment macular edema secondary to branch
retinal vein occlusion. AAMJ. 2011; 9(2): 68-80.
Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, et al. Intravitreal bevacizumab
injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina.
; 27(8): 1004-12. doi: 10.1097/IAE.0b013e3180ed458d. doi: 10.1097/IAE.0b013e3180ed458d. PMID:
Astam N, Batioglu F, Ozmert E. Short-term efficacy of intravitreal bevacizumab for the treatment of
macular edema due to diabetic retinopathy and retinal vein occlusion. Int Ophthalmol. 2009; 29(5): 343-8.
doi: 10.1007/s10792-008-9242-2. PMID: 18553061.
Costa RA, Jorge R, Calucci D, Melo LA Jr., Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for
central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007; 27(2): 141-9. doi:
1097/IAE.0b013e31802eff83. PMID: 17290194.
Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;
(3): 234-8. doi: 10.1097/ICU.0b013e3282fb7fb0. PMID: 18408499.
Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. Intravitreal
bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as
primary treatment of diabetic macular edema. Retina. 2007; 27(9): 1187-95. doi:
1097/IAE.0b013e31815ec261. PMID: 18046223.
Tao Y, Hou J, Jiang YR, Li XX, Jonas JB. Intravitreal bevacizumab vs triamcinolone acetonide for macular
oedema due to central retinal vein occlusion. Eye (Lond). 2010; 24(5): 810-5. doi: 10.1038/eye.2009.220.
PMID: 19696805.
Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Pathogenesis of macular edema
with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and
interleukin-6. Am J Ophthalmol. 2005; 140(2): 256-61. doi: 10.1016/j.ajo.2005.03.003. PMID: 16086947.
Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection
of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004; 122(3): 336-40. doi:
1001/archopht.122.3.336. PMID: 15006845.
Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone
acetonide. Br J Ophthalmol. 2003; 87(1): 24-7. PMID: 12488256, PMCID: PMC1771462.
Lau LI, Chen KC, Lee FL, Chen SJ, Ko YC, Liu CJ, et al. Intraocular pressure elevation after intravitreal
triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol. 2008; 146(4): 573-8. doi:
1016/j.ajo.2008.05.034. PMID: 18639860.
Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular
pressure. Am J Ophthalmol. 2004; 138(5): 740-3. doi: 10.1016/j.ajo.2004.06.067. PMID: 15531307.
Hsu J, Kaiser RS, Sivalingam A, Abraham P, Fineman MS, Samuel MA, et al. Intravitreal bevacizumab
(avastin) in central retinal vein occlusion. Retina. 2007; 27(8): 1013-9. DOI:
1097/IAE.0b013e318050ca7c. PMID: 18040237.
Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al. Intravitreal
bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.
Retina. 2006; 26(3): 279-84. PMID: 16508427.
Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection
of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers
Imaging. 2005; 36(4): 336-9. PMID: 16156153.
Spandau UH, Ihloff AK, Jonas JB. Intravitreal bevacizumab treatment of macular oedema due to central
retinal vein occlusion. Acta Ophthalmol Scand. 2006; 84(4): 555-6. doi: 10.1111/j.1600- 0420.2006.00740.x. PMID: 16879582.
Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J
Ophthalmol. 2006; 90(12): 1542-7. doi: 10.1136/bjo.2006.098426. PMID: 17114590, PMCID:
PMC1857529.
Gillies MC. What we don't know about avastin might hurt us. Arch Ophthalmol. 2006; 124(10): 1478-9.
doi: 10.1001/archopht.124.10.1478. PMID: 17030717.
Schlingemann RO. Role of growth factors and the wound healing response in age-related macular
degeneration. Graefes Arch Clin Exp Ophthalmol. 2004; 242(1): 91-101. doi: 10.1007/s00417-003-0828-0.
PMID: 14685874.
Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. A phase II
randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for
diabetic macular edema. Ophthalmology. 2005; 112(10): 1747-57. doi: 10.1016/j.ophtha.2005.06.007.
PMID: 16154196.
Ekdawi NS, Bakri SJ. Intravitreal triamcinolone and bevacizumab combination therapy for macular edema
due to central retinal vein occlusion refractory to either treatment alone. Eye (Lond). 2007; 21(8): 1128-30.
doi: 10.1038/sj.eye.6702903. PMID: 17585312.
Ehrlich R, Ciulla TA, Moss AM, Harris A. Combined treatment of intravitreal bevacizumab and intravitreal
triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp
Ophthalmol. 2010; 248(3): 375-80. doi: 10.1007/s00417-009-1211-6. PMID: 19898827.
Jin E, Luo L, Bai Y, Zhao M. Comparative effectiveness of intravitreal bevacizumab with or without
triamcinolone acetonide for treatment of diabetic macular edema. Ann Pharmacother. 2015; 49(4): 387-97.
doi: 10.1177/1060028014568006. PMID: 25622852.
Wang HY, Li X, Wang YS, Zhang ZF, Li MH, Su XN, et al. Intravitreal injection of bevacizumab alone or
with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion. Int J
Ophthalmol. 2011; 4(1): 89-94. doi: 10.3980/j.issn.2222-3959.2011.01.21. PMID: 22553618, PMCID:
PMC3340676.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
